Abatacept for the treatment of adults with psoriatic arthritis: patient selection and perspectives

Figures & data

Table 1 Data from key Phase III randomized-controlled trials of non-TNFi biologics use in PsA

Study	Intervention	ACR20	ACR50	ACR70	PASI75	Change in HAQ-DI
ASTRAEA^Citation19	ABT	ABT 39.4%^*	ABT 19.2%	ABT 10.3%	ABT 16.4%	ABT −0.33
		PBO 22.3%	PBO 12.3%	PBO 6.6%	PBO 10.1%	PBO −0.2
PSUMMIT 2^Citation26	UST	UST45 43.7%^*	UST45 17.5%^*	UST45 6.8%	UST45 51.3%^*	UST45 −0.13^*
		UST90 43.8%^*	UST90 22.9%^*	UST90 8.6%	UST90 55.6%^*	UST90 −0.25^*
		PBO 20.2%	PBO 6.7%	PBO 2.9%	PBO 5%	PBO 0
FUTURE 2^Citation11	SEC	SEC150 51%^*	SEC150 35%	SEC150 21%	SEC150 48%^*	SEC150 −0.48
		SEC300 54%^*	SEC300 35%^*	SEC300 20%	SEC300 63%^*	SEC300 −0.56^*
		PBO 15%	PBO 7%	PBO 1%	PBO16%	PBO −0.31
PALACE 1^Citation12	APR	APR30 36.6%^*	APR30 19.9%^*	APR30 10.6%^*	APR30 21%^*	APR30 −0.26^*
		PBO 13.3%	PBO 4.2%	PBO 0.6%	PBO 4.6%	PBO −0.08
SPIRIT-P1^Citation25	IXE ADA (active reference)	IXEQ2W 62.1%^*	IXEQ2W 46.6%^*	IXEQ2W 34%^*	IXEQ2W 79.7%^*	IXEQ2W −0.50^*
		IXEQ4W 57.9%^*	IXEQ4W 40.2%^*	IXEQ4W 23.4%^*	IXEQ4W 71.2%^*	IXEQ4W −0.44^*
		ADA 57.4%^*	ADA 38.6%^*	ADA 25.7%^*	ADA 54.4%^*	ADA −0.37^*
		PBO 30.2%	PBO 15.1%	PBO 5.7%	PBO 10.4%	PBO −0.18
OPAL Broaden^Citation54	TOF ADA (active reference)	TOF 50%^*	TOF 28%^*	TOF 17%^*	TOF 43%^*	TOF −0.35^*
		ADA 52%	ADA 33%	ADA 19%	ADA 39%	ADA −0.38
		PBO 33%	PBO 10%	PBO 5%	PBO 15%	PBO −0.18

Notes: Improvements in PsA disease activity, physical function, and psoriasis severity are measured the ACR20/50/70 responses, change in HAQ-DI score, and PASI75 response. All endpoints were tested at study week 24, except for the OPAL Broaden study, which assessed outcomes at month 3. APR is a nonbiologic drug. ACR20/50/70: a minimum of 20, 50, and 70% improvement in the ACR response; PASI75: at least a 75% improvement in the PASI score; ABT: ABT 125 mg SQ weekly; UST45: UST 45 mg at weeks 0 and 4 and then every 12 weeks; UST90: UST 90 mg at weeks 0 and 4 and then every 12 weeks; SEC150: SEC 150 mg SQ weekly for 4 weeks and then every 4 weeks; SEC300: SEC 300 mg SQ weekly for 4 weeks and then every 4 weeks; APR 30: APR at 30 mg by mouth twice daily; IXEQ2W: IXE 160 mg once and then 80 mg SQ every 2 weeks; IXEQ4W: IXE 160 mg once and then 80 mg every 4 weeks; ADA: ADA 40 mg SQ every 2 weeks; TOF: TOF at 5 mg BID. ^*Statistically significant results of each intervention when compared with placebo.

Abbreviations: ABT, abatacept; ACR, American College of Rheumatology; ADA, adalimumab; APR, apremilast; HAQ-DI, Health Assessment Questionnaire Disability Index; IXE, ixekizumab; PASI, Psoriasis Area-and-Severity Index; PBO, placebo; PsA, psoriatic arthritis; SEC, secukinumab; SQ, subcutaneous; TNFi, tumor necrosis factor inhibitor; TOF, tofacitinib; UST, ustekinumab.

MeasePJGottliebABvan der HeijdeDEfficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritisAnn Rheum Dis20177691550155828473423

 PubMed Web of Science ®Google Scholar

RitchlinCRahmanPKavanaughAPSUMMIT 2 Study GroupEfficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trialAnn Rheum Dis201473699099924482301

 PubMed Web of Science ®Google Scholar

McInnesIBMeasePJKirkhamBFUTURE 2 Study GroupSecukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet201538699991137114626135703

 PubMed Web of Science ®Google Scholar

KavanaughAMeasePJGomez-ReinoJJTreatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitorAnn Rheum Dis20147361020102624595547

 PubMed Web of Science ®Google Scholar

MeasePJVan Der HeijdeDRitchlinCTSPIRIT-P1 Study GroupIxekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1Ann Rheum Dis2017761798727553214

 PubMed Web of Science ®Google Scholar

MeasePHallSFitzGeraldOTofacitinib or adalimumab versus placebo for psoriatic arthritisN Engl J Med2017377161537155029045212

 PubMed Web of Science ®Google Scholar